Immunome — Third Quarter 2026 Earnings Summary

Immunome, Inc. reported a net loss of $85.8 million for the third quarter ended September 30, 2026, with total cash, cash equivalents, and marketable securities amounting to $461.6 million. The company's lead candidate, varegacestat, received a PDUFA target action date of April 28, 2027, from the U.S. FDA and had its Marketing Authorization Application validated by the European Medicines Agency. Clinical updates included objective responses across all dose levels for the ROR1-targeted ADC IM-1021 in B-cell non-Hodgkin lymphoma and the receipt of Investigational New Drug clearance for the solid tumor ADC IM-1340. Additionally, first-in-human trials were initiated for the ADC IM-1617 and the FAP-targeted radioligand therapy IM-3050 during the quarter.